New hope for non-Hodgkins lymphoma patients AbbVie to launch epcoritamab in the United Arab Emirates

–  UAE is the first country after the country of origin (US) to be granted conditional regulatory approval

Dubai, United Arab Emirates, Sep. 12, 2023

TEPKINLY™ (epcoritamab) has received conditional regulatory approval in the United Arab Emirates (UAE) on August 15^th 2023, being the first country after the country of origin (United States) to grant conditional regulatory approval. This milestone marks a significant step forward in the field of oncology and offers new hope for patients. TEPKINLY™ (epcoritamab) is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.

TEPKINLY™ (epcoritamab) is the First and Only Subcutaneous Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL).⁶

Continue reading AbbVie to launch epcoritamab in the United Arab Emirates →